VK Paul

New variants of Covid-19 virus not behind the fresh surge in cases: Government

Two variants of SARS CoV 2 -- N440K and E484K -- have been detected in Maharashtra, Kerala and Telangana.

published on : 23rd February 2021

'Concerns about adverse events unfounded': Centre says Covid vaccine hesitancy must end

"Let me assure you that adverse events are not even taking place to a significant scale, said V K Paul, member (health), Niti Aayog who also heads the national task force on Covid-19.

published on : 19th January 2021

Enough stockpile of COVID-19 vaccine for inoculation of priority groups in first phase: Niti Aayog member V K Paul 

Paul noted that "three to four months from now, there will be other vaccines and the stockpile will be even bigger."

published on : 4th January 2021

Approval to vaccines 'turning point' in India's fight against COVID-19: NITI Aayog

NITI Aayog member VK Paul on Sunday said the speed with which scientists and the industry came together to meet this challenge epitomizes the spirit and potential of 'Aatmanirbhar Bharat'.

published on : 3rd January 2021

New coronavirus strain: No need to change existing treatment protocol, says National Task Force

The NTF recommended that 5% of all positive samples from every state be subjected to whole genome sequencing to track the mutations in coronavirus in India.

published on : 26th December 2020

Delhi experiencing third wave of COVID-19, no need to panic: CM Arvind Kejriwal

Considering the trend, I would call it a third wave. Because by September end and October beginning, cases had started to drop...it went below 3,000.

published on : 5th November 2020

Don’t be too hopeful: Government on vaccine

The Centre on Tuesday cautioned against pinning too much hope on the Covid-19 vaccines, saying everyone wants them to succeed but there is no guarantee, they will.

published on : 19th August 2020

COVID-19 vaccine panel to discuss procurement, logistics and priority groups on August 12

The committee on vaccine administration will engage with all stakeholders including state governments and vaccine manufacturers and its terms of reference include selecting suitable vaccines.

published on : 11th August 2020